We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Nativis entered into a license agreement in 2017 for the development of the technology for the treatment of adults with glioblastoma multiforme in the Japanese market. Read More
The FDA used a Q&A format to issue final guidance on an informal, non-binding process for sponsors to obtain preliminary feedback before submitting marketing applications. Read More
The FDA said the Banyan Brain Trauma Indicator has the potential “to rule out the need for a CT scan in at least one-third patients who are suspected of having mTBI.” Read More